FDA Post-Marketing Safety Decisions

Donald F. Klein, MD

Published: August 15, 2006

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

The U.S. Food and Drug Administration (FDA) black box warning that antidepressants increase the risk of suicidal thinking and behavior in children was followedby a sharp fall in antidepressant prescriptions. No procedure for estimating the net public health impact exists.1 No suicide occurred in clinical trials of approximately 4400 children, but the term suicidality clearly implies a high degree of lethal risk.’ ‹

Volume: 67

Quick Links: Psychopharmacology

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Clinical and Practical Psychopharmacology

Antipsychotic Augmentation With N-Acetylcysteine for Patients With Schizophrenia

Dr Andrade discusses whether or not recent findings support the use of NAC as antipsychotic augmentation in...

Read More...